





Age/Gender : 27 Y 7 M 21 D/F
UHID/MR No : CINR.0000154514
Visit ID : CINROPV199931

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 8639274453 Collected : 22/Jul/2023 08:51AM
Received : 22/Jul/2023 10:47AM
Reported : 22/Jul/2023 04:08PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOEEMI - MEDIWHEEL - EIILL RODY	/ HEALTH ANNUAL	DI LIS CHECK -	FEMALE - 2D ECHO - E	DAN INDIA - EV2324	
ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	
i est ivallie	Result	Oilit	Dio. Itel. Italige	Method	

PCV RBC COUNT MCV MCH	40.00 4.77 83.9	% Million/cu.mm	36-46 3.8-4.8	Electronic pulse & Calculation
MCV		Million/cu.mm	2010	Calculation
	83.9		3.8-4.8	Electrical Impedence
MCH		fL	83-101	Calculated
	28.1	pg	27-32	Calculated
MCHC	33.5	g/dL	31.5-34.5	Calculated
R.D.W	14.8	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	6,880	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (D	LC)			
NEUTROPHILS	60.6	%	40-80	Electrical Impedanc
LYMPHOCYTES	27.5	%	20-40	Electrical Impedanc
EOSINOPHILS	2.3	%	1-6	Electrical Impedance
MONOCYTES	9.5	%	2-10	Electrical Impedanc
BASOPHILS	0.1	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	4169.28	Cells/cu.mm	2000-7000	Electrical Impedanc
LYMPHOCYTES	1892	Cells/cu.mm	1000-3000	Electrical Impedanc
EOSINOPHILS	158.24	Cells/cu.mm	20-500	Electrical Impedanc
MONOCYTES	653.6	Cells/cu.mm	200-1000	Electrical Impedanc
BASOPHILS	6.88	Cells/cu.mm	0-100	Electrical Impedanc
PLATELET COUNT	316000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	16	mm at the end of 1 hour	0-20	Modified Westergre

RBCs: are normocytic normochromic

WBCs: are normal in total number with normal distribution and morphology.

PLATELETS: appear adequate in number.

HEMOPARASITES: negative

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE

Page 1 of 13









: Mrs.CHELE URMILA DEVI

Age/Gender

: 27 Y 7 M 21 D/F

UHID/MR No Visit ID : CINR.0000154514 : CINROPV199931

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 8639274453

Collected

: 22/Jul/2023 08:51AM

Received

: 22/Jul/2023 10:47AM : 22/Jul/2023 04:08PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL -	- FULL BODY HEALTH ANNUA!	L PLUS CHECK - FEMALE - 2D E	CHO - PAN INDIA - FY2324
/			00

Test Name Result

Unit

Bio. Ref. Range

Method

Page 2 of 13



SIN No:BED230170951







: Mrs.CHELE URMILA DEVI

Age/Gender

: 27 Y 7 M 21 D/F

UHID/MR No Visit ID : CINR.0000154514 : CINROPV199931

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 8639274453

Collected

: 22/Jul/2023 08:51AM

Received

: 22/Jul/2023 10:47AM

Reported

Status

: 22/Jul/2023 03:15PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		

BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA				
BLOOD GROUP TYPE	0	Microplate Hemagglutination		
Rh TYPE	Positive	Microplate Hemagglutination		

Page 3 of 13





Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)









Age/Gender : 27 Y 7 M 21 D/F
UHID/MR No : CINR.0000154514
Visit ID : CINROPV199931

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 8639274453 Collected : 22/Jul/2023 08:51AM

Received : 22/Jul/2023 11:09AM

Reported : 22/Jul/2023 12:56PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

GLUCOSE, FASTING, SODIUM FLUORIDE	89	mg/dL	70-100	HEXOKINASE
PLASMA				

Comment:

As per American Diabetes Guidelines

Interpretation
Normal
Prediabetes
Diabetes

GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2	75	mg/dL	70-140	HEXOKINASE
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Ref: Marks medical biochemistry and clinical approach









: Mrs.CHELE URMILA DEVI

Age/Gender

: 27 Y 7 M 21 D/F

UHID/MR No Visit ID : CINR.0000154514

Ref Doctor

: CINROPV199931

Emp/Auth/TPA ID

: Dr.SELF : 8639274453 Collected

: 22/Jul/2023 08:51AM

Received

: 22/Jul/2023 11:09AM

Reported

: 22/Jul/2023 12:56PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		
HBA1C, GLYCATED HEMOGLOBIN,	5.7	%		HPLC		
WHOLE BLOOD EDTA						
ESTIMATED AVERAGE GLUCOSE (eAG) ,	117	mg/dL		Calculated		
WHOLE BLOOD EDTA						

Comment:

Reference Range as per American Diabetes Association (ADA):

REFERENCE GROUP	HBA1C IN %
NON DIABETIC ADULTS >18 YEARS	<5.7
AT RISK (PREDIABETES)	5.7 – 6.4
DIAGNOSING DIABETES	≥ 6.5
DIABETICS	
· EXCELLENT CONTROL	6 – 7
· FAIR TO GOOD CONTROL	7 – 8
· UNSATISFACTORY CONTROL	8 – 10
· POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. A1C test should be performed at least two times a year in patients who are meeting treatment goals (and who have stable glycemic control).
- 2. Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1 and type 2 diabetes. When mean annual HbA1c is <1.1 times ULN (upper limit of normal), renal and retinal complications are rare, but complications occur in >70% of cases when HbA1c is >1.7 times ULN.
- 3. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present. Fructosamine may be used as an alternate measurement of glycemic control

Page 5 of 13



SIN No:PLF02003212,PLP1351704,EDT230067486







Age/Gender : 27 Y 7 M 21 D/F
UHID/MR No : CINR.0000154514
Visit ID : CINROPV199931

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 8639274453 Collected : 22/Jul/2023 08:51AM
Received : 22/Jul/2023 10:40AM
Reported : 22/Jul/2023 11:59AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

LIPID PROFILE, SERUM				
TOTAL CHOLESTEROL	178	mg/dL	<200	CHO-POD
TRIGLYCERIDES	121	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	45	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	133	mg/dL	<130	Calculated
LDL CHOLESTEROL	109	mg/dL	<100	Calculated
VLDL CHOLESTEROL	24.2	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.96		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Measurements in the same patient can show physiological and analytical variations.

NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.

Page 6 of 13



SIN No:SE04430152









: Mrs.CHELE URMILA DEVI

Age/Gender

: 27 Y 7 M 21 D/F

UHID/MR No Visit ID : CINR.0000154514 : CINROPV199931

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 8639274453 Collected

: 22/Jul/2023 08:51AM

Received Reported : 22/Jul/2023 10:40AM : 22/Jul/2023 11:59AM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

			<u> </u>	
ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324				
Test Name	Result	Unit	Bio. Ref. Range	Method

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.69	mg/dL	0.3–1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.10	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.59	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	10	U/L	<35	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	15.0	U/L	<35	IFCC
ALKALINE PHOSPHATASE	77.00	U/L	30-120	IFCC
PROTEIN, TOTAL	7.16	g/dL	6.6-8.3	Biuret
ALBUMIN	4.08	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	3.08	g/dL	2.0-3.5	Calculated
A/G RATIO	1.32		0.9-2.0	Calculated

Page 7 of 13











: Mrs.CHELE URMILA DEVI

Age/Gender

: 27 Y 7 M 21 D/F

UHID/MR No Visit ID : CINR.0000154514

Ref Doctor

: CINROPV199931 : Dr.SELF

Emp/Auth/TPA ID :

: 8639274453

Collected

: 22/Jul/2023 08:51AM

Received

: 22/Jul/2023 10:40AM

Reported

: 22/Jul/2023 11:59AM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM				
CREATININE	0.61	mg/dL	0.72 – 1.18	JAFFE METHOD
UREA	14.10	mg/dL	17-43	GLDH, Kinetic Assay
BLOOD UREA NITROGEN	6.6	mg/dL	8.0 - 23.0	Calculated
URIC ACID	4.39	mg/dL	2.6-6.0	Uricase PAP
CALCIUM	9.40	mg/dL	8.8-10.6	Arsenazo III
PHOSPHORUS, INORGANIC	3.47	mg/dL	2.5-4.5	Phosphomolybdate Complex
SODIUM	135	mmol/L	136–146	ISE (Indirect)
POTASSIUM	4.1	mmol/L	3.5–5.1	ISE (Indirect)
CHLORIDE	103	mmol/L	101–109	ISE (Indirect)

Page 8 of 13











: Mrs.CHELE URMILA DEVI

Age/Gender

: 27 Y 7 M 21 D/F

UHID/MR No Visit ID

: CINR.0000154514

Ref Doctor

: CINROPV199931

Emp/Auth/TPA ID

: Dr.SELF

: 8639274453

Collected

: 22/Jul/2023 08:51AM

Received

: 22/Jul/2023 10:40AM

Reported Status

: 22/Jul/2023 11:59AM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL	L BODY HEALTH ANNUAL PLUS CHECK :	- FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

GAMMA GLUTAMYL TRANSPEPTIDASE	19.00	U/L	<38	IFCC	
(GGT), SERUM					

Page 9 of 13







Emp/Auth/TPA ID





Patient Name : Mrs.CHELE URMILA DEVI

: 8639274453

Age/Gender : 27 Y 7 M 21 D/F

UHID/MR No : CINR.0000154514 Visit ID : CINROPV199931

Ref Doctor : Dr.SELF

Collected : 22/Jul/2023 08:51AM
Received : 22/Jul/2023 10:39AM
Reported : 22/Jul/2023 11:37AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY	HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	AN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

THYROID PROFILE TOTAL (T3, T4, TSH),	SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	1.13	ng/mL	0.7-2.04	CLIA
THYROXINE (T4, TOTAL)	9.91	μg/dL	6.09-12.23	CLIA
THYROID STIMULATING HORMONE (TSH)	0.933	μIU/mL	0.34-5.60	CLIA

Comment:

Serum TSH concentrations exhibit a diurnal variation with the peak occurring during the night and the nadir occurring between 10 a.m. and 4 p.m.In primary hypothyroidism, thyroid-stimulating hormone (TSH) levels will be elevated. In primary hyperthyroidism, TSH levels will be low. Elevated or low TSH in the context of normal free thyroxine is often referred to as subclinical hypo- or hyperthyroid-ism, respectively. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy.

Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.

Note:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)			
First trimester	0.1 - 2.5			
Second trimester	0.2 - 3.0			
Third trimester	0.3 - 3.0			

Page 10 of 13













 Age/Gender
 : 27 Y 7 M 21 D/F

 UHID/MR No
 : CINR.0000154514

 Visit ID
 : CINROPV199931

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 8639274453 Collected : 22/Jul/2023 08:51AM
Received : 22/Jul/2023 11:13AM
Reported : 22/Jul/2023 11:45AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
AROOF EITH MEDITIFIED TOLE DOD'T HEALTH ARROAD TEOD OFFICER TEMPLE 2D 2010 TARRING TEMPLE					
Test Name	Result	Unit	Bio. Ref. Range	Method	

COMPLETE URINE EXAMINATION (CUE), URINE						
PHYSICAL EXAMINATION						
COLOUR	PALE YELLOW		PALE YELLOW	Visual		
TRANSPARENCY	HAZY		CLEAR	Visual		
рН	5.5		5-7.5	DOUBLE INDICATOR		
SP. GRAVITY	1.010		1.002-1.030	Bromothymol Blue		
BIOCHEMICAL EXAMINATION						
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR		
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE		
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION		
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE		
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION		
BLOOD	POSITIVE		NEGATIVE	Peroxidase		
NITRITE	NEGATIVE		NEGATIVE	Diazotization		
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE		
CENTRIFUGED SEDIMENT WET MOUNT AND MICROSCOPY						
PUS CELLS	1-2	/hpf	0-5	Microscopy		
EPITHELIAL CELLS	2-3	/hpf	<10	MICROSCOPY		
RBC	1-2	/hpf	0-2	MICROSCOPY		
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY		
CRYSTALS	ABSENT		ABSENT	MICROSCOPY		

Page 11 of 13













: Mrs.CHELE URMILA DEVI

Age/Gender

: 27 Y 7 M 21 D/F

UHID/MR No

: CINR.0000154514

Visit ID

: CINROPV199931

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 8639274453

Collected

: 22/Jul/2023 12:21PM

Received

: 22/Jul/2023 05:39PM

: Final Report

Reported Status : 22/Jul/2023 06:46PM

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL	PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

URINE GLUCOSE(POST PRANDIAL),				
URINE				

NEGATIVE

NEGATIVE

Dipstick

Page 12 of 13



SIN No:UPP015196





: Mrs.CHELE URMILA DEVI

Age/Gender UHID/MR No : 27 Y 7 M 21 D/F : CINR.0000154514

Visit ID

: CINROPV199931

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: 8639274453

Collected

: 22/Jul/2023 08:51AM

Received Reported

: 22/Jul/2023 11:13AM : 22/Jul/2023 11:30AM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

URINE GLUCOSE(FASTING), URINE	NEGATIVE	NEGATIVE	Dipstick

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

Dr. Prasanna M.B.B.S, M.D

Consultant Pathologist

Dr.Nisha

M.B.B.S,MD(Pathology) Consultant Pathologist

Dr. Anita Shobha Flynn M.B.B.S MD (Pathology)

Consultant Pathologist

DR.SHIVARAJA SHETTY M.B.B.S.M.D(Biochemistry M.B.B.S.MD(Pathology) CONSULTANT BIOCHEMIST Consultant Pathologist

Dr.Anita Shobha Flynn

Page 13 of 13





: CINROPV199931

: 22-07-2023 20:36

OP Visit No

Reported on

Specimen

Patient Name : Mrs. Chele Urmila Devi Age/Gender : 27 Y/F

UHID/MR No.

: CINR.0000154514

Sample Collected on LRN#

Ref Doctor : SELF Emp/Auth/TPA ID : 8639274453

: RAD2054199

DEPARTMENT OF RADIOLOGY

X-RAY CHEST PA

Both lung fields and hila are normal.

No obvious active pleuro-parenchymal lesion seen.

Both costophrenic and cardiophrenic angles are clear.

Both diaphragms are normal in position and contour.

Thoracic wall and soft tissues appear normal.

CONCLUSION:

No obvious abnormality seen

Dr. PRIYA B MBBS, MD (Radiology) Radiology



Patient Name : Mrs. Chele Urmila Devi Age/Gender : 27 Y/F

 UHID/MR No.
 : CINR.0000154514
 OP Visit No
 : CINROPV199931

 Sample Collected on
 : 22-07-2023 17:21

Ref Doctor : SELF Emp/Auth/TPA ID : 8639274453

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

LIVER: Appears normal in size, shape and echopattern. No focal parenchymal lesions identified. No evidence of intra/extrahepatic biliary tree dilatation noted. Portal vein appears to be of normal size.

GALLBLADDER: Moderately distended. No definite calculi identified. No evidence of abnormal wall thickening noted.

SPLEEN: Appears normal in size, shape and echopattern. No focal parenchymal lesions identified.

PANCREAS: Obscured by bowel gas. However, the visualized portion appear normal.

KIDNEYS: Both kidneys appear normal in size, shape and echopattern. Corticomedullary differentiation appears maintained. No evidence of calculi or hydronephrosis on either side.

Right kidney measures 9.3X4.3 cm.

Left kidney measures 10.0X5.0 cm.

URINARY BLADDER: Distended and appears normal. No evidence of abnormal wall thickening noted.

UTERUS: Anteverted and appears normal in size. Myometrial echoes appear normal. The endometrial lining appears intact. Endometrium measures 9 mm.

OVARIES: Both ovaries appear normal in size and echopattern.

No free fluid is seen.

IMPRESSION:

NO SIGNIFICANT SONOGRAPHIC ABNORMALITY DETECTED.

Dr. RAMESH G
MBBS DMRD
RADIOLOGY